Search

Your search keyword '"Sverre E"' showing total 22 results
Start Over Author "Sverre E" Journal the lancet
22 results on '"Sverre E"'

1. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Author

Rahimi, Kazem, Bidel, Zeinab, Nazarzadeh, Milad, Copland, Emma, Canoy, Dexter, Wamil, Malgorzata, Majert, Jeannette, McManus, Richard, Adler, Amanda, Agodoa, Larry, Algra, Ale, Asselbergs, Folkert W, Beckett, Nigel S, Berge, Eivind, Black, Henry, Boersma, Eric, Brouwers, Frank P J, Brown, Morris, Brugts, Jasper J, Bulpitt, Christopher J, Byington, Robert P, Cushman, William C, Cutler, Jeffrey, Devereaux, Richard B, Dwyer, Jamie P, Estacio, Ray, Fagard, Robert, Fox, Kim, Fukui, Tsuguya, Gupta, Ajay K, Holman, Rury R, Imai, Yutaka, Ishii, Masao, Julius, Stevo, Kanno, Yoshihiko, Kjeldsen, Sverre E, Kostis, John, Kuramoto, Kizuku, Lanke, Jan, Lewis, Edmund, Lewis, Julia B, Lievre, Michel, Lindholm, Lars H, Lueders, Stephan, MacMahon, Stephen, Mancia, Giuseppe, Matsuzaki, Masunori, Mehlum, Maria H, Nissen, Steven, Ogawa, Hiroshi, Ogihara, Toshio, Ohkubo, Takayoshi, Palmer, Christopher R, Patel, Anushka, Pfeffer, Marc Allan, Pitt, Bertram, Poulter, Neil R, Rakugi, Hiromi, Reboldi, Gianpaolo, Reid, Christopher, Remuzzi, Giuseppe, Ruggenenti, Piero, Saruta, Takao, Schrader, Joachim, Schrier, Robert, Sever, Peter, Sleight, Peter, Staessen, Jan A, Suzuki, Hiromichi, Thijs, Lutgarde, Ueshima, Kenji, Umemoto, Seiji, van Gilst, Wiek H, Verdecchia, Paolo, Wachtell, Kristian, Whelton, Paul, Wing, Lindon, Woodward, Mark, Yui, Yoshiki, Yusuf, Salim, Zanchetti, Alberto, Zhang, Zhen-Yu, Anderson, Craig, Baigent, Colin, Brenner, Barry Morton, Collins, Rory, de Zeeuw, Dick, Lubsen, Jacobus, Malacco, Ettore, Neal, Bruce, Perkovic, Vlado, Rodgers, Anthony, Rothwell, Peter, Salimi-Khorshidi, Gholamreza, Sundström, Johan, Turnbull, Fiona, Viberti, Giancarlo, Wang, Jiguang, Chalmers, John, Davis, Barry R, Pepine, Carl J, and Teo, Koon K

Published
2021
Full Text
View/download PDF

4. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Author

Rahimi, Kazem, primary, Bidel, Zeinab, additional, Nazarzadeh, Milad, additional, Copland, Emma, additional, Canoy, Dexter, additional, Ramakrishnan, Rema, additional, Pinho-Gomes, Ana-Catarina, additional, Woodward, Mark, additional, Adler, Amanda, additional, Agodoa, Larry, additional, Algra, Ale, additional, Asselbergs, Folkert W, additional, Beckett, Nigel S, additional, Berge, Eivind, additional, Black, Henry, additional, Brouwers, Frank P J, additional, Brown, Morris, additional, Bulpitt, Christopher J, additional, Byington, Robert P, additional, Cushman, William C, additional, Cutler, Jeffrey, additional, Devereaux, Richard B, additional, Dwyer, Jamie, additional, Estacio, Ray, additional, Fagard, Robert, additional, Fox, Kim, additional, Fukui, Tsuguya, additional, Gupta, Ajay K, additional, Holman, Rury R, additional, Imai, Yutaka, additional, Ishii, Masao, additional, Julius, Stevo, additional, Kanno, Yoshihiko, additional, Kjeldsen, Sverre E, additional, Kostis, John, additional, Kuramoto, Kizuku, additional, Lanke, Jan, additional, Lewis, Edmund, additional, Lewis, Julia B, additional, Lievre, Michel, additional, Lindholm, Lars H, additional, Lueders, Stephan, additional, MacMahon, Stephen, additional, Mancia, Giuseppe, additional, Matsuzaki, Masunori, additional, Mehlum, Maria H, additional, Nissen, Steven, additional, Ogawa, Hiroshi, additional, Ogihara, Toshio, additional, Ohkubo, Takayoshi, additional, Palmer, Christopher R, additional, Patel, Anushka, additional, Pfeffer, Marc Allan, additional, Pitt, Bertram, additional, Poulter, Neil R, additional, Rakugi, Hiromi, additional, Reboldi, Gianpaolo, additional, Reid, Christopher, additional, Remuzzi, Giuseppe, additional, Ruggenenti, Piero, additional, Saruta, Takao, additional, Schrader, Joachim, additional, Schrier, Robert, additional, Sever, Peter, additional, Sleight, Peter, additional, Staessen, Jan A, additional, Suzuki, Hiromichi, additional, Thijs, Lutgarde, additional, Ueshima, Kenji, additional, Umemoto, Seiji, additional, van Gilst, Wiek H, additional, Verdecchia, Paolo, additional, Wachtell, Kristian, additional, Whelton, Paul, additional, Wing, Lindon, additional, Yui, Yoshiki, additional, Yusuf, Salim, additional, Zanchetti, Alberto, additional, Zhang, Zhen-Yu, additional, Anderson, Craig, additional, Baigent, Colin, additional, Brenner, Barry Morton, additional, Collins, Rory, additional, de Zeeuw, Dick, additional, Lubsen, Jacobus, additional, Malacco, Ettore, additional, Neal, Bruce, additional, Perkovic, Vlado, additional, Rodgers, Anthony, additional, Rothwell, Peter, additional, Salimi-Khorshidi, Gholamreza, additional, Sundström, Johan, additional, Turnbull, Fiona, additional, Viberti, Giancarlo, additional, Wang, Jiguang, additional, Chalmers, John, additional, Teo, Koon K, additional, Pepine, Carl J, additional, and Davis, Barry R, additional

Published
2021
Full Text
View/download PDF

5. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Author

Poulter, Neil R., Wedel, Hans, Dahlof, Bjorn, Sever, Peter S., Beevers, D. Gareth, Caulfield, Mark, Kjeldsen, Sverre E., Kristinsson, Arni, McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, Ostergren, Jan, and Pocock, Stuart

Subjects
Hypertension -- Drug therapy, Hypertension -- Complications and side effects, Cardiovascular diseases -- Drug therapy, Cardiovascular diseases -- Patient outcomes, Antihypertensive drugs -- Evaluation
Published
2005

6. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Author

Dahlof, Bjorn, Sever, Peter S., Poulter, Neil R., Wedel, Hans, Beevers, D. Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E., Kristinsson Ami McInnes, Gordon T., Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergen, Jan

Subjects
Hypertension -- Drug therapy, Antihypertensive drugs -- Evaluation, Antihypertensive drugs -- Dosage and administration
Published
2005

7. Take a blood pressure pill or undergo renal denervation?

Author

Murray D. Esler and Sverre E. Kjeldsen

Subjects
Denervation, Kidney, business.industry, medicine.medical_treatment, General Medicine, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Blood pressure, medicine.anatomical_structure, Sympathectomy, Pill, Anesthesia, Medicine, 030212 general & internal medicine, business
Published
2018

8. INSIGHT and NORDIL

Author

Kjeldsen, Sverre E, Westheim, Arne S, and Os, Ingrid

Published
2000

9. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Author

Lindholm, Lars H, Ibsen, Hans, Dahlöf, Björn, Devereux, Richard B, Beevers, Gareth, de Faire, Ulf, Fyhrquist, Frej, Julius, Stevo, Kjeldsen, Sverre E, Kristiansson, Krister, Lederballe-Pedersen, Ole, Nieminen, Markku S, Omvik, Per, Oparil, Suzanne, Wedel, Hans, Aurup, Peter, Edelman, Jonathan, and Snapinn, Steven

Published
2002
Full Text
View/download PDF

11. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Author

Adler, Amanda, Agodoa, Larry, Algra, Ale, Asselbergs, Folkert W, Beckett, Nigel S, Berge, Eivind, Black, Henry, Brouwers, Frank P J, Brown, Morris, Bulpitt, Christopher J, Byington, Robert P, Chalmers, John, Cushman, William C, Cutler, Jeffrey, Davis, Barry R, Devereaux, Richard B, Dwyer, Jamie, Estacio, Ray, Fagard, Robert, Fox, Kim, Fukui, Tsuguya, Gupta, Ajay K, Holman, Rury R, Imai, Yutaka, Ishii, Masao, Julius, Stevo, Kanno, Yoshihiko, Kjeldsen, Sverre E, Kostis, John, Kuramoto, Kizuku, Lanke, Jan, Lewis, Edmund, Lewis, Julia B, Lievre, Michel, Lindholm, Lars H, Lueders, Stephan, MacMahon, Stephen, Mancia, Giuseppe, Matsuzaki, Masunori, Mehlum, Maria H, Nissen, Steven, Ogawa, Hiroshi, Ogihara, Toshio, Ohkubo, Takayoshi, Palmer, Christopher R, Patel, Anushka, Pepine, Carl J, Pfeffer, Marc Allan, Pitt, Bertram, Poulter, Neil R, Rakugi, Hiromi, Reboldi, Giuseppe, Reid, Christopher, Remuzzi, Giuseppe, Ruggenenti, Piero, Saruta, Takao, Schrader, Joachim, Schrier, Robert, Sever, Peter, Sleight, Peter, Staessen, Jan A, Suzuki, Hiromichi, Thijs, Lutgarde, Ueshima, Kenji, Umemoto, Seiji, van Gilst, Wiek H, Verdecchia, Paolo, Wachtell, Kristian, Whelton, Paul, Wing, Lindon, Woodward, Mark, Yui, Yoshiki, Yusuf, Salim, Zanchetti, Alberto, Zhang, Zhen-Yu, Anderson, Craig, Baigent, Colin, Brenner, Barry Morton, Collins, Rory, de Zeeuw, Dick, Lubsen, Jacobus, Malacco, Ettore, Neal, Bruce, Perkovic, Vlado, Rodgers, Anthony, Rothwell, Peter, Salimi-Khorshidi, Gholamreza, Sundström, Johan, Turnbull, Fiona, Viberti, Giancarlo, and Wang, Jiguang

Abstract

The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.

Published
2021
Full Text
View/download PDF

13. Diuretics in the LIFE study

Author

Kato, Johji, Eto, Tanenao, Dahlof, Bjorn, Devereux, Richard B., and Kjeldsen, Sverre E.

Published
2004

14. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

Author

Julius, Stevo, Kjeldsen, Sverre E., Weber, Michael, Brunner, Hans R., Ekman, Steffan, Hansson, Lennart, Hua, Tsushung, Laragh, John, McInnes, Gordon T., Mitchell, Lada, Plat, Francis, Schork, Anthony, Smith, Beverly, and Zanchetti, Alberto

Subjects
Valsartan (Medication) -- Research, Valsartan (Medication) -- Influence, Antihypertensive drugs -- Influence, Antihypertensive drugs -- Research, Hypertension -- Drug therapy, Hypertension -- Research, Cookery for hypertensives -- Drug therapy, Cookery for hypertensives -- Research
Published
2004

15. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

Author

Weber, Michael A., Julius, Stevo, Kjeldsen, Sverre E., Brunner, Hans R., Ekman, Steffan, Hansson, Lennart, Hua, Tsushung, Laragh, John H., McInnes, Gordon T., Mitchell, Lada, Plat, Francis, Schork, M. Anthony, Smith, Beverly, and Zanchetti, Alberto

Subjects
Valsartan (Medication) -- Research, Valsartan (Medication) -- Influence, Blood pressure -- Research, Blood pressure -- Drug therapy, Antihypertensive drugs -- Influence, Antihypertensive drugs -- Research
Published
2004

16. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. (Articles)

Author

Sever, Peter S, Dahlof, Bjorn, Poulter, Neil R, Wedel, Hans, Beevers, Gareth, Caulfield, Mark, Collins, Rory, Kjeldsen, Sverre E, Kristinsson, Arni, McInnes, Gordon T, Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, and Ostergren, Jan

Subjects
Cholesterol -- Measurement, Coronary heart disease -- Prevention, Hypertension -- Health aspects, Cookery for hypertensives
Published
2003

17. INSIGHT and NORDIL

Author

Garcia-Lopez, Fernando J, Alvaro, Fernando de, Bertram, Mathias, Achard, Jean-Michel, Oudart, Nicole, Aldigier, Jean-Claude, Fournier, A, Georgita, A, Bouffandeau, B, Oprisiu, R, Avanzini, Fausto, Tognoni, Gianni, Palmer, Christopher R, Brown, Morris J, Hansson, Lennart, Lund-Johansen, Per, Lanke, Jan, Kjeldsen, Sverre E, Westheim, Arne S, and Os, Ingrid

Subjects
Hypertension, Nifedipine -- Dosage and administration
Published
2000

18. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Author

Hans Wedel, Gareth Beevers, Lars H Lindholm, Björn Dahlöf, Krister Kristiansson, Markku S. Nieminen, Steven M. Snapinn, Frej Fyhrquist, Ulf de Faire, Hans Ibsen, Sverre E. Kjeldsen, Jonathan M. Edelman, Richard B. Devereux, Stevo Julius, Ole Lederballe-Pedersen, Suzanne Oparil, Peter Aurup, and Per Omvik

Subjects
medicine.medical_specialty, Framingham Risk Score, medicine.drug_class, business.industry, General Medicine, Atenolol, medicine.disease, Placebo, Surgery, law.invention, Clinical trial, Losartan, Randomized controlled trial, law, Internal medicine, Diabetes mellitus, medicine, Antihypertensive drug, business, medicine.drug
Abstract

Summary Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients. Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of leftventricular hypertrophy (LVH) on electrocardiograms losartanbased or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4·7 years [1·1]). We used Cox regression analysis with baseline Framingham risk score and

Published
2002

19. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Author

Sverre E. Kjeldsen, Ulf de Faire, Richard B. Devereux, Per Omvik, Stevo Julius, Ole Lederballe-Pedersen, Björn Dahlöf, Hans Ibsen, Krister Kristiansson, Hans Wedel, Lars H Lindholm, Suzanne Oparil, Gareth Beevers, Frej Fyhrquist, and Markku S. Nieminen

Subjects
Male, medicine.medical_specialty, Losartan/hydrochlorothiazide, Left ventricular hypertrophy, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists, Double-Blind Method, Internal medicine, Diabetes mellitus, medicine, Humans, cardiovascular diseases, Antihypertensive Agents, Perindopril/indapamide, Aged, Aged, 80 and over, business.industry, General Medicine, Middle Aged, Atenolol, medicine.disease, Angiotensin II, Surgery, Blood pressure, Cardiovascular Diseases, Hypertension, Cardiology, Female, business, medicine.drug
Abstract

Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death.We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens.Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=0.001); and myocardial infarction (non-fatal and fatal) occurred in 198 and 188, respectively (1.07, 0.88-1.31, p=0.491). New-onset diabetes was less frequent with losartan. Interpretation Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction in blood pressure and is better tolerated. Losartan seems to confer benefits beyond reduction in blood pressure.

Published
2002

20. Diuretics in the LIFE study

Author

Björn Dahlöf, Sverre E. Kjeldsen, and Richard B. Devereux

Subjects
medicine.medical_specialty, business.industry, medicine, General Medicine, Intensive care medicine, business, Life study
Published
2004

21. Warning for antihypertensiv durg

Author

Sverre E. Kjeldsen

Subjects
Drug labeling, Information retrieval, Text mining, business.industry, MEDLINE, Medicine, General Medicine, business
Published
2001

22. INSIGHT and NORDIL

Author

Ingrid Os, Sverre E. Kjeldsen, and Arne Westheim

Subjects
Text mining, Information retrieval, business.industry, MEDLINE, Medicine, General Medicine, business
Published
2000

Catalog

Books, media, physical & digital resources
See catalog results